Novartis, Molecular Partners Report Positive Data for Covid-19 Treatment Ensovibep
January 10 2022 - 2:09AM
Dow Jones News
By Ed Frankl
Novartis AG and Molecular Partners AG on Monday reported
positive topline data from their antiviral Covid-19 treatment
ensovibep, and will seek expedited regulatory authorizations
globally.
The results from a Phase 2 study of 407 patients receiving a
single intravenous dose of ensovibep showed a 78% reduction in
hospitalization or emergency-room visits related to Covid-19
compared with a placebo, and a improvement in time to a clinical
recovery, Novartis said.
The ensovibep treatment continues to maintain protection against
variants of concern identified so far, including Omicron, the
Basel-based drugmaker said.
Novartis also said it will exercise its option and pay 150
million Swiss francs ($163.3 million) to in-license ensovibep from
Molecular Partners and accelerate manufacturing scale-up.
It also plans to seek expedited regulatory authorizations
globally, first via the U.S. Food and Drug Administration's
emergency-use authorization.
If approved, ensovibep will be the first multispecific antiviral
molecule for the treatment of Covid-19, Novartis said.
Write to Ed Frankl at edward.frankl@dowjones.com
(END) Dow Jones Newswires
January 10, 2022 01:54 ET (06:54 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024
